outcomes of patients with monocytic aml treated with venetoclax & azacitidine
Published 1 year ago • 252 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
1:19
the outcomes of patients with primary refractory and relapsed acute leukemia
-
7:27
menin inhibitors in aml: mechanism of action, the current key data, and predicting efficacy
-
3:40
outcomes of all stratified by socioeconomic factors
-
1:34
captivate study: outcomes in patients with umrd following cessation of ibrutinib plus venetoclax
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
1:33
phase i trial results for oral azacitidine and venetoclax in r/r aml
-
3:03
outcomes following venetoclax monotherapy in patients with r/r wm in the real-world setting
-
5:00
diagnosing and treating al amyloidosis: a 2020 update from dr morie gertz
-
7:50
which aml patients benefit most from venetoclax treatment?
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:35
outcomes of allosct following blinatumomab in children and young adults with r/r b-all
-
1:08
the importance of predicting venetoclax response in patients with aml
-
1:18
venetoclax combination therapies in aml
-
1:24
omniverse: safety and tolerability of oral azacitidine plus venetoclax in patients with aml
-
2:26
magrolimab plus azacitidine in treatment-naïve aml
-
2:44
azacitidine, venetoclax & gilteritinib in older/unfit patients with flt3-mutated aml
-
2:25
venetoclax for aml
-
1:02
maintenance therapy following treatment for amyloidosis
-
3:52
venetoclax & aml
-
3:42
mechanisms of resistance to venetoclax in aml and methods being explored to overcome these
-
1:33
outcomes of reduced intensity allosct in patients with accelerated-phase myelofibrosis